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Abstract 
 
 
 Heterocycles have many applications in the discipline of medicinal chemistry. 
These structures are found in various natural products with relevant biological activity. 
Our research group, in collaboration with two others, is particularly interested in one 
heterocycle, quinoline, as a scaffold for HIV-1 integrase inhibitors. A synthetic route has 
been developed to produce a derivatized structure on small scale. One goal of this thesis 
was to expand the scale of this route to provide increased quantities of the quinoline 
scaffold. Procedures were adapted to accommodate the increase in scale to convert 
commercially available anthranilic acids to quinolines via the isatoic anhydride. The 
quinolines could then be further derivatized to be tested as HIV-1 integrase inhibitors. At 
a later stage in the synthesis, the use of a masked acyl cyanide (MAC) reagent allows 
installation of an alpha-alkoxyester side chain onto the quinoline that is necessary for 
HIV inhibition. The second goal of this thesis involves heterocycles more broadly by 
expanding this reaction to include other heterocycles to test the generality of the method. 
This reaction also highlights the utility of MAC reagents as an example of umpolung 
chemistry, which is a reversal of polarity and bond formation compared to what is 
traditionally accomplished. These exciting strategies open the possibility for new 
reagents and strategies in organic synthesis. A series of heterocyclic structures were 
tested in the MAC reaction and the results of the method are discussed. 
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1.Introduction 
 Heterocycles are a class of molecule present in many biomolecules within the 
human body and contain atoms other than carbon and hydrogen within a ring. The natural 
presence of heterocycles as well as their complexity and ability to hydrogen bond makes 
them desirable structures for use as drugs. Medicinal chemists synthesize drug structures 
containing heterocycles that mimic the compounds found in our bodies with the goal of 
being able to enhance or restrict the intended function of those molecules. One 
heterocycle of interest is quinoline, which contains two fused six-membered benzene 
rings with one carbon switched out for a nitrogen. It has been identified as a scaffold for 
drug structures with the ability to inhibit HIV-1 integrase via binding to an allosteric site. 
While the allosteric site is not the active site, binding to it still affects the structure of the 
active site by changing the conformation of the enzyme and rendering it unable to 
perform its function. Quinolines can be purchased commercially or synthesized and then 
in each case derivatized to the final target. However, commercially available quinolines 
are often not as flexible as ones that can be synthesized from simpler substrates, where 
functional groups can be introduced at various positions. A synthetic strategy for the 
ability to create quinolines with substitutions at various positions has been developed on 
a small scale. The ability to scale up is valuable for being able to create a variety of 
derivatized quinolines to test as HIV-1 integrase inhibitors. 
 One position that is essential to inhibition of the enzyme is the 3-position of 
quinoline. The desired quinoline motif includes an acetic acid residue at this site. It was 
determined that addition of a masked acyl cyanide (MAC) reagent to the 3-position 
would install the correct functional group and oxidation state. It is of interest to extend 
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this highly valuable method to other heterocycles as well. The success of this method 
could potentially indicate another pathway to derivatize heterocycles useful in the 
synthesis of other drug structures.  
2. Background 
2.1 HIV Introduction 
The human immunodeficiency virus, HIV, is a retrovirus, which is a virus that 
contains RNA that is reverse transcribed into DNA upon infection of a cell. The virus 
attacks the body’s T-cells, white blood cells that develop in the thymus, which in turn 
weakens the immune system and prevents those infected from being able to fight off 
other infections. The body is unable to eliminate HIV and, if the disease is left untreated, 
it can lead to acquired immunodeficiency syndrome, or AIDS. An AIDS infection often 
leads to opportunistic infections and cancers because of the body’s inability to counteract 
them.1  
HIV was first discovered after many cases of what would later be known as AIDS 
were detected in 1981. The HIV-1 virus was isolated in 1983 in France and was known at 
the time as the lymphoadenopathy-associated virus or LAV. The virus was cloned and 
sequenced in 1985, making it possible for viral load and resistance tests to be developed. 
Sequencing allowed the relationship of HIV-1 to be determined as the cross-species 
transmission of the simian immunodeficiency virus, SIV. After isolation of HIV-1, it was 
determined that the CD4 T cell was the main receptor for HIV.2 Since HIV was known to 
be cytopathic, or cause the death of cells, the discovery that CD4 cells were targeted led 
to the use of cell counting to monitor those diagnosed with the disease.  
2.2 Statistics 
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More than three decades after its discovery, HIV still remains a leading cause of 
death around the world. A total of 1.8 million people were newly diagnosed with HIV in 
2017 alone. A staggering 36.9 million people are estimated to be living with HIV while 
approximately 35 million are estimated to have died from AIDS-related illnesses since 
the beginning of the epidemic. Sub-Saharan Africa is the region known to be the most 
heavily infected with 66% of new infections in 2017 being located in this region.3 The 
high infection rate is due to the poverty in the area which results in a lack of education, 
young marriage, and a sex trade.4  
In the United States, HIV diagnoses are not equal across regions. Per 100,000 
people, the South has the highest rate with 16.1%.5 In 2014, Mississippi was ranked 9th in 
the nation for number of new HIV diagnoses and among metropolitan areas, Jackson was 
ranked 4th in the nation. In 2017, Forrest County was ranked 4th in HIV diagnoses in 
Mississippi.6 These sobering statistics show how truly close to home this disease is and 
how it impacts the lives of many Mississippi residents. 
2.3 HIV Life Cycle 
HIV is spread through the exchange of bodily fluids through blood transfusions, 
sexual intercourse, contaminated needles, or from mother to child during pregnancy. As a 
virus by definition, HIV is not able to sustain on its own and requires a host cell to 
reproduce. HIV targets the CD4 helper T-cells in the host, which are responsible for 
regulating immune responses in the body. As the number of HIV virus particles increases 
and CD4 cells are destroyed, the host’s immune system is weakened. Once inside a CD4 
cell, HIV takes over the cell’s ability to transcribe and translate its own DNA and in turn 
produces more virus particles (Figure 2.1). Early stage replication involves the virus 
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binding to the cell surface up through viral DNA integration to the host DNA. Late stage 
replication is the beginning of viral transcription and ends with the release of the fully 
developed virion.7  
Binding of the virus to the CD4 receptor also involves a co-receptor, CCR5 (C-C 
motif chemokine receptor 5).8,9 CD4 binding causes a conformation change in the HIV-
Env trimer, a glycoprotein on the surface of viruses, which then interacts with the co-
receptor causing the virus coating to fuse with the cell membrane.10 Fusion with the 
membrane causes the transfer of the material inside the viral particle into the cytoplasm. 
Once the genetic material is inside the cell, the single strand RNA is transcribed into 
double stranded DNA via an enzyme called reverse transcriptase, that is characteristic of 
retroviruses like HIV. After reverse transcription, the viral capsid has to be disassembled 
and this is known as uncoating. Capsids have been shown to remain in the cytoplasm for 
several hours giving HIV a critical stability necessary for infection. This step is closely 
tied to the reverse transcription and the integration of viral DNA. Now that the viral 
genetic material is double stranded DNA, it can be incorporated into the host DNA by 
way of the integrase enzyme. As the host cell’s DNA is replicated, the viral DNA is 
replicated along with it.8 
Transcription involves the conversion of DNA into RNA. Segments of RNA 
encode for viral components called Tat, Rev, and Nef. Tat functions for viral 
transcription and RNA elongation. Rev monitors the transport of RNA into the 
cytoplasm. Nef causes the cell to be less detectable by the immune system, therefore 
making the cell a more effective producer of viral particles. These components are 
assembled in a complex process involving many proteins. Gag and Gag-Pol precursors 
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multimerize via interactions between the Gag proteins. These precursors are concentrated 
in lipid rafts in the cell membrane. Glycoproteins are used to build platforms through 
interactions with the matrix proteins. Then two copies of viral RNA are accumulated with 
viral proteins at the plasma membrane and form a membrane-coated spherical particle.8 
The viral particles are then released after HIV’s Vpu transmembrane protein overcomes 
the cell’s tetherin protein.11 These particles are not infectious until they are mature after a 
viral protease protein cleaves Gag and Gag-Pol precursors to their mature form.8  
 
Figure 2.1: HIV Life Cycle2 
2.4 HIV Treatments 
HIV has several factors that contribute to its ability to continue to thrive over the 
years. HIV has a high mutation rate of 1 error per 10,000 nucleotides, a short generation 
time, and a large virus production of 2x109 particles per day. Therefore, treatment 
strategies for HIV often contain a cocktail of drugs that serve to target multiple phases of 
the life cycle. This approach is known as HAART, or highly active antiretroviral 
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therapy.8,12 There are seven types of drug classes: nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), integrase strand-transfer inhibitors (INSTIs), chemokine receptor 
antagonists (CCR5), fusion inhibitors (FIs), and entry inhibitors (CD4-directed post-
attachment inhibitors). These seven classes target five phases of the HIV reproductive 
cycle as shown in Figure 2.1.13 Currently, the US Food and Drug Administration (FDA) 
has approved a total of 22 medicines to treat HIV. One drug regimen assigned to a patient 
usually consists of three medicines from two or more drug classes (Table 2.1).14 
Name NRTI nNRTI INSTI 
Pharmacokinetic 
enhancer 
Triumeq Abacavir Lamivudine Dolutegravir -- 
Juluca -- Rilpivirine Dolutegravir -- 
Stribild 
Tenofovir disoproxil 
fumarate/emtricitabine 
-- Elvitegravir Cobicistat 
Genvoya 
Tenofovir 
alafenamide/ 
emtricitabine 
-- Elvitegravir Cobicistat 
Atripla 
Tenofovir disoproxil 
fumarate/emtricitabine 
Efavirenz -- -- 
Complera 
Tenofovir disoproxil 
fumarate/emtricitabine 
Rilpivirine -- -- 
Odefsey 
Tenofovir 
alafenamide/ 
emtricitabine 
Rilpivirine -- -- 
Biktarvy 
Tenofovir 
alafenamide/ 
emtricitabine 
-- Bictegravir -- 
Table 2.1: Common HAART HIV-1 Treatments 
 
Each drug class is briefly described in the following section including their role in 
preventing the replication of HIV. NRTIs were the first available drug class. They are 
structurally similar to DNA nucleoside bases and prevent proviral DNA from being 
synthesized by incorporating themselves as a faulty bases into the growing chain. 
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NNRTIs bind at an allosteric pocket of the reverse transcriptase dimer, changing the 
conformation of the enzyme and altering the active site. PIs are competitive inhibitors of 
HIV protease and prevent Gag and Gag-Pol polypeptides from being cleaved. INSTIs 
target the active site of the HIV integrase enzyme and bind metal ions in the active site, 
which prevents binding to the host DNA. CCR5 antagonists interact with the CCR5 co-
receptors and prevent the binding of viral particles to the CD4 cells. Only one FI is on the 
market due to its complicated production and inconvenient administration (subcutaneous 
injection). It functions by preventing the conformation change of necessary proteins that 
allow the binding of HIV particles to the cell membrane. The first CD4 post-attachment 
inhibitor was approved in March 2018 and prevents the CD4 receptor-HIV complex from 
interacting with its intended co-receptor.14  
2.5 Integrase Inhibitors 
The unique structure of HIV-1 integrase is not similar to any human enzymes, 
which means that there is a low risk of adverse effects from medications targeting this 
enzyme. There are only three FDA approved medications that target the integrase 
enzyme. All three are INSTIs that act at the active site, and include raltegravir, 
elvitegravir, and dolutegravir. Unfortunately, resistance to two of these drugs, raltegravir 
and elvitegravir, has been discovered, creating a need for more medications in this drug 
class.14 Since the viral mutations have affected the active site, other potential sites for 
enzyme inhibition must be explored.15  
The activity of integrase is monitored by various proteins. Human lens 
epithelium-derived growth factor (LEDGF) and endogeneous transcriptional coactivator 
(p75) have been found to be important co-factors in the integration of viral DNA. The 
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interaction between two of the integrase protein domains, the catalytic core domain 
(CCD) and the integrase binding domain (IBD), have revealed necessary protein-protein 
interactions. The LEDGF/p75b complex stabilizes the interactions between domains and 
helps to form the functional tetramer. Targeting this allosteric pocket could be a way to 
prevent the enzyme function and avoid viral mutations at this site.16 
Allosteric integrase inhibitors (ALLINIs) have been found to compete with 
LEDGF/p75 binding interactions and are capable of disrupting enzyme function.17,18 
These inhibitors work through a dual mode of action - they prevent the interaction of 
integrase and viral DNA and inhibit the integrase-LEDGF binding.19 A high-throughput 
screen (HTS) was carried out using the Boehringer Ingelheim compound collection to 
identify hits based on a quinoline scaffold resembling compound 1. Analogues were 
synthesized to do structure-activity relationship (SAR) studies to determine leads. SAR 
studies involve modifying a portion of the drug and then re-submitting it to testing to see 
if the change increases its potency and/or favorable properties. The conclusion of the 
studies produced compound 2 (BI-224436) as the first non-catalytic site integrase 
inhibitor (NCINI) to advance to a phase 1 clinical trial.20 
 
Figure 2.2: Quinoline scaffold and BI-224436 
2.6 Umpolung Chemistry 
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Organic synthesis reactions are commonly based on the polar nature of bonds and 
the interactions between electrophiles, the electron accepting component, and 
nucleophiles, the electron donating component.21 Umpolung chemistry involves the 
inversion of polarity as to what is traditionally thought of as electrophile versus 
nucleophile (in other words, the reversal of positive and negative, respectively, as in 
Figure 2.2). This technique is highly useful in organic chemistry bond-forming processes 
by allowing seemingly impossible transformations usually prohibited by traditional 
reactivity rules. One example of an umpolung process involves the use of an acyl anion 
equivalent.22 Technically, the acyl anion itself does not exist in the reaction, but rather, a 
substrate is used such that bond formation appears to have resulted from the acyl anion. 
The substrate that “acts” as an acyl anion is called an acyl anion synthetic equivalent or 
synthon. These synthons have the power to be a traceless linchpin and join two separate 
molecules without ever being a distinct acyl anion. Masked acyl cyanides (MACs) are 
acyl anion synthons that are capable of acting as nucleophiles and electrophiles, allowing 
a chemist to customize the nucleophile and electrophile to be utilized.23 For example, 
when a MAC reagent is reacted with an aldehyde electrophile and then an alcohol 
nucleophile, they can be used to install an α-alkoxy ester functional group to a 
molecule.24  
 
Figure 2.3: Comparison of normal and umpolung reactivity 
R R’
O
R R’
O
Umpolung reactivityNormal reactivity
R
O
R
O O
R
O
R
O O
  10 
2.7 Heterocycles in Drug Structures 
A heteroatom is any atom other than carbon and hydrogen. This term is used 
because carbon and hydrogen make up the largest percent of organic compounds. 
Examples of common heteroatoms found in organic compounds include largely oxygen 
and nitrogen, but also halogens, phosphorus, and sulfur. Heteroatoms provide molecules 
with diversity and enhanced polarity to perform their intended biological functions and to 
design new therapeutics. Heterocycles, which are ring molecules containing at least one 
heteroatom, are present in over 70% of all drug structures.25 They are a component of 
seven of the top ten prescribed drugs in 2016, demonstrating their importance in 
medicinal chemistry (heterocycles within each structure are highlighted in blue, Figure 
2.4).26 Drugs are often made to mimic structural motifs of the body’s natural nucleic 
acids, amino acids, and carbohydrates. In this way, heterocycles serve as bioisosteres, or 
biologically similar functional groups, in drug candidates to ensure they will have similar 
function in the body. Their usefulness stems from the ability to form noncovalent 
interactions in the body via hydrogen bonding, whether that is as hydrogen-bond 
acceptors (heteroaromatics) or donors (saturated nitrogen heterocycles). The ability to 
hydrogen bond can improve qualities necessary for drug molecules such as lipophilicity, 
polar surface area, and oral bioavailability.27 
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Figure 2.4: Top 10 drugs from 2016 containing heterocycles 
3. Materials and Methods 
3.1 Materials 
Starting materials and solvents were purchased from commercial vendors and 
used without purification unless noted. Thin-layer chromatography (TLC) was performed 
using Sorbent Technologies 250 m glass-backed UV254 silica plates. The plates were 
first visualized by fluorescence upon 254 nm irradiation. The plates were then dipped in 
phosphomolybdic acid (PMA) stain followed by heating. Column chromatography was 
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performed using Sorbent Technologies 40-63 µm, pore size 60 Å silica gel with solvent 
systems indicated. All yields refer to isolated material that is chromatographically (TLC) 
and spectroscopically (1H NMR) homogenous.  
3.2 Analysis and Characterization 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker 
UltraShield Plus 400 MHz spectrometer and chemical shifts are recorded in parts per 
million from an internal deuterated solvent peak of chloroform (7.26 ppm) or 
dimethylsulfoxide (2.50 ppm) on the  scale and are reported as follows: chemical shift 
[multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet), coupling 
constant(s) in hertz, integration, interpretation]. Carbon (13C NMR) data were recorded 
on the same instrument at a frequency of 100 MHz and are reported as follows: chemical 
shift (multiplicity as determined from DEPT-135 and DEPT-90 NMR (quaternary (s), 
methine (d), methylene (t), methyl (q)). 
3.3 Large Scale Synthesis of Derivatized Quinoline 
The synthetic route (Scheme 3.1) has the goal of synthesizing the final quinoline 
product 7 on large scale. It begins with 5-bromoanthranilic acid 3 (25 g) and converts it 
to an isatoic anhydride 4 using triphosgene in tetrahydrofuran (THF). The isatoic 
anhydride 4 (10 g) was transformed to quinoline 5 with ethyl acetoacetate in 
dimethylaniline (DMA) catalyzed by sodium hydroxide (NaOH). The alcohol group on 
the 4-position was chlorinated using phosphoryl chloride (POCl3) on a 10 g scale. The 
resulting quinoline was further derivatized by a graduate student to produce the desired 
final product 7. 
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Scheme 3.2: Large scale synthesis of derivatized quinoline 
Experimental Information 
7-Bromo-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (4): 2-Amino-4-
bromobenzoic acid (0.115 mol, 1 eq) was added to a 1000 mL 3 neck 
round bottom flask with a stir bar. THF (350 mL) was then added to the flask. 
Triphosgene (0.115 mol, 1 eq) was dissolved in THF (50 mL) and was added to the 3 
neck flask via addition funnel. A reflux condenser was added and the flask was heated to 
70 °C and stirred for 20 hours. The reaction was cooled to room temperature and 
transferred to a 4 L beaker with distilled water (400 mL). The beaker was stirred with 
mechanical stirring for 6 hours. The solid was filtered out using a Buchner funnel and 
washed with water. The solid was collected and stirred with methanol (50 mL) for 10 
minutes then re-filtered and washed with methanol. The solid was collected and dried 
under high vacuum to produce 24.6908 g (89%) of a pearlescent solid. Characterization 
data can be found in the literature.28 
Ethyl 7-bromo-4-hydroxy-2-methylquinoline-3-carboxylate (5): 7-
Bromo-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (0.04 mol, 1 eq), 
ethyl acetoacetate (0.08 mol, 2 eq), and DMA (0.6 M) were added to a 250 mL round 
bottom flask with stir bar. NaOH (0.04 mol, 1 eq) was then added to the flask, followed 
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by a reflux condenser, and the reaction was heated to 100 °C for 7 hours. The reaction 
was allowed to cool then was transferred to a 600 mL beaker with distilled water (250 
mL) and stirred with mechanical stirring overnight. The white solid was filtered using a 
Buchner funnel and washed with distilled water. The solid was collected and dried under 
high vacuum to afford 10.2777 g (80%). Characterization can be found in literature.29  
Ethyl 7-bromo-4-chloro-2-methylquinoline-3-carboxylate (6): 
Ethyl 7-bromo-4-hydroxy-2-methylquinoline-3-carboxylate (0.03 
mole, 1 eq) and POCl3 (0.5 M) were added to a 250 mL round bottom flask containing a 
stir bar. The reaction was heated to 80 °C for 1 hour, at which time TLC was used to 
check for completion. The reaction was heated for 1 hour increments until complete. 
Once complete, the reaction was cooled to room temperature and then transferred to a 
separatory funnel and added dropwise to an ice bath in a 4 L beaker due a large exotherm. 
The initial flask and separatory funnel were rinsed with distilled water. Then 10 M NaOH 
was added to neutralize the reaction. The reaction was filtered using a Buchner funnel 
and a tan solid was isolated and dried under high vacuum to produce 10.1834 g (97%). 
Characterization data can be found in literature.29 
3.4 MAC Addition to Aromatic Heterocycles  
 Masked acyl cyanide reagents (MAC) can be added to heterocyclic aldehydes 
(Scheme 3.2). The reaction utilizes 4-dimethylaminopyridine (DMAP) as the base to 
deprotonate the MAC reagent and ethanol (EtOH) serves to capture the acyl cyanide 
formed in situ. The method from literature was adapted to this procedure.25  
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Scheme 3.2: Generalized scheme for MAC addition to heterocyclic aldehydes 
Experimental Information 
General procedure: To a 5 mL conical vial and spin vane were added 2-((tert-
butyldimethylsilyl)oxy)malononitrile 9 (0.32 mmol, 1.05 eq), aldehyde starting material 8 
(0.3 mmol, 1 eq), diethyl ether (Et2O, 0.15 M), EtOH (0.9 mmol, 3 eq), and DMAP (0.75 
mmol, 2.5 eq). The reaction was stirred at room temperature for 16 hours. TLC was used 
to monitor starting material consumption, and in cases where this was difficult due to 
overlap of spots, 1H NMR was taken (and compared to the 1H NMR of the starting 
materials). After completion of the reaction, it was added to a 30 mL separatory funnel 
and extracted using dichloromethane (DCM, 3 x 10 mL portions) and the combined 
organic layers were then washed with saturated aqueous ammonium chloride (NH4Cl, 10 
mL). The organic layer was collected, dried over sodium sulfate (Na2SO4) and 
concentrated under air. After confirming reaction completion by crude 1H NMR, the 
concentrated organic layer was dissolved in DCM and loaded onto a 4 g column packed 
with SiO2 and hexanes. The products were eluted with a mixture of ethyl acetate (EtOAc) 
in hexanes.  
Ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(1H-indol-3-yl) acetate 
(11): The starting material was 3-indolecarboxaldehyde. The 
concentrated organic layer produced a orange-brown oil. The column 
was run with 50 mL each of hexanes then 5-10-20% EtOAc/hexanes. The product-rich 
fractions were collected and concentrated under air to produce a green oil (0.0359 g, 36% 
O
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yield). 1H NMR (CDCl3, 400 MHz) δ: 8.12 (s, 1H), 7.82 (d, J=7.8 Hz, 1H), 7.35 (d, J=8.2 
Hz, 1H), 7.27 (d, J=4.3 Hz, 1H), 7.20 (ddd, J=7.7, 7.5, 1.3 Hz, 1H), 7.13 (dd, J=7.5, 7.4 
Hz, 1H), 5.53 (s, 1H), 4.15 (dq, J=7.2, 7.1 Hz, 1H), 4.14 (dq, J=7.3, 7.1 Hz, 1H), 1.22 (t, 
J=7.8, 7.1 Hz, 3H), 0.92 (s, 9H), 0.13 (s, 3H), 0.03 (s, 3H). 13C NMR (CDCl3, 100 MHz) 
δ: 172.5 (s), 136.4 (s), 125.6 (s), 122.7 (d), 122.2 (d), 120.3 (d), 119.8 (d), 115.1 (s), 
110.1 (d), 69.3 (d), 61.0 (t), 29.7 (s), 25.8 (d), 18.7 (q) 14.3 (q), -5.0 (q), -5.1 (q). 
Ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(pyridine-2-yl) acetate (12): 
The starting material was 2-pyridinecarboxaldehyde. The organic layer 
was concentrated under air to produce a yellow/orange solid. The column was run with 
50 mL each of hexanes then 5-10-20% EtOAc/hexanes. The fractions containing product 
were collected and concentrated under air to produce a yellow oil (0.0327 g, 37% yield). 
1H NMR (CDCl3, 400 MHz) δ: 8.52 (ddd, J=4.8, 1.8, 0.8 Hz, 1H), 7.71 (ddd, J=8.0, 7.8, 
1.8 Hz, 1H), 7.58 (d, J=7.9, 1H), 7.20 (ddd, J=7.5, 4.9, 1.2 Hz, 1H), 5.34 (s, 1H), 4.19 
(dq, J=14.3, 7.2 Hz, 1H), 4.17 (dq, J=14.2, 7.1 Hz, 1H), 1.22 (t, J=7.2, 3H), 0.91 (s, 9H), 
0.13 (s, 3H), 0.06 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ: 171.4 (s), 159.0 (s), 148.9 (d), 
137.0 (d), 123.0 (d), 120.9 (d), 76.3 (d), 63.4 (t), 25.8 (q), 18.4 (s), 14.2 (q), -4.9 (q), -5.1 
(q). 
Ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(pyridine-3-yl) acetate (13): 
3-Pyridinecarboxaldehyde was the starting material. The organic layer 
was concentrated under air to produce a yellow solid. The column was run with 50 mL 
9% EtOAc/hexanes and 100mL 12% EtOAc/hexanes to produce a yellow oil (0.0639 g, 
72% yield). 1H NMR (CDCl3, 400 MHz) δ: 8.71(d, J=2.36 Hz, 1H), 8.55 (dd, J=4.9, 1.6 
Hz, 1H), 7.82 (dt, J=8.0, 1.7 Hz, 1H), 7.28 (ddd, J=8.0, 4.8, 0.5 Hz, 1H), 5.24 (s, 1H), 
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4.19-4.12 (m, 2H), 1.22 (t, J=7.1 Hz, 3H), 0.91 (s, 9H), 0.14 (s, 3H), 0.06 (s, 3H). 13C 
NMR (CDCl3, 100 MHz) δ: 171.4 (s), 149.4 (d), 148.1 (d), 134.8 (s), 133.9 (d), 123.4 (d), 
72.4 (d), 61.5 (t), 25.7 (d), 18.3 (s), 14.1 (d), -5.1 (q), -5.2 (q). 
 Ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(quinolin-yl) acetate 
(14): The starting material was 2-quinolinecarboxaldehyde. The 
column was run with 50 mL each of hexanes then 5-10% EtOAc/hexanes to afford a 
yellow oil (0.0342 g, 33% yield). 1H NMR (CDCl3, 400MHz) δ: 8.19 (d, J=9.1 Hz, 1H), 
8.10 (dd, J=8.2, 0.8 Hz, 1H), 7.81 (dd, J=8.0, 1.2 Hz, 1H), 7.73 (d, J=8.5 Hz, 1H), 7.71-
7.69 (m, 1H), 7.54 (ddd, J=8.7, 7.5, 1.2 Hz, 1H), 5.51 (s, 1H), 4.19 (dq, J=14.3, 7.5 Hz, 
1H), 4.17 (dq, J=14.2, 7.5 Hz, 1H), 1.21 (t, J=8.0, 7.2 Hz, 3H), 0.93 (s, 9H), 0.16 (s, 3H), 
0.07 (s, 3H). 13C NMR (CDCl3, 100MHz) δ: 171.1 (s), 159.0 (s), 147.3 (d), 137.0 (d), 
129.5 (d), 129.4 (d), 127.8 (d), 127.6 (d), 126.6 (s), 118.7 (d), 77.0 (d), 61.3 (t), 30.9 (s), 
25.7 (q), 18.3 (q), -4.9 (q), -5.1 (q).  
 Ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(thiophen-2-yl) acetate (15): 
The starting material was 2-thiophenecarboxaldehyde. The column was 
run with 50 mL each of hexanes then 5-10% EtOAc/hexanes to produce a yellow brown 
oil. (0.0216 g, 24% yield). 1H NMR (CDCl3, 400 MHz) δ: 7.25 (dd, J=5.1, 1.2 Hz, 1H), 
7.06 (dt, J=3.5, 1.5, 1.0 Hz, 1H) 6.96 (dd, J=5.2, 3.6 Hz, 1H), 5.46 (d, J=0.8, 1H), 4.21 
(dq, J=7.2, 1.7 Hz, 1H), 4.20 (dq, J=7.1, 1.7 Hz, 1H), 1.27 (t, J=7.2 Hz, 3H), 0.94 (s, 9H), 
0.13 (s, 3H), 0.08 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ: 171.1 (s), 142.8 (s), 126.6 (d), 
125.3 (d), 124.5 (d), 71.0 (d), 61.4 (t), 61.4 (t), 25.7 (q), 18.4 (s), 14.1 (q), -5.1 (q), -5.3 
(q). 
4. Results and Discussion 
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4.1 Large Scale Synthesis of Derivatized Quinoline 
 The new route utilizing various anthranilic acids to form the quinolines through 
an isatoic anhydride (3 → 6) allows substitution that using a commercially available 
quinoline 16 cannot (Schemes 4.1 and 4.2). First, the prior route utilized quinoline 16 
which only allows functionalization at the 4-position (where the OH group is attached, 
Scheme 4.1). In addition, the prior route used a Grignard reaction (17 → 18) to install the 
side chain at the 3-position. However, during this reaction, a byproduct 19 was observed 
with no substitution at the 3-position and the yield of the reaction suffered as the scale of 
the reaction increased (Scheme 4.1). The prior route still allowed the Pigza, Donahue, 
and Kessl groups to fully explore substitution at the 4-position.29 
The new route has addressed both the generality of functionalizing at other 
positions and approached installation of the 3-position in an alternative manner (Scheme 
4.2). The ability to produce a quinoline scaffold that can be derivatized at the 5-, 6-, 7-, 
and 8-positions in large scale is beneficial for the capacity to produce many different 
derivatives for testing as potential HIV integrase inhibitors. The current route will discuss 
7-position substitution, due to starting with bromoanthranilic acid 3, which is 
commercially available. The other anthranilic acids are also available, allowing for 
exploration of the previously mentioned sites.  
 
Scheme 4.3: Grignard reaction after halogenation of commercially available quinoline 
N
OH
N
Br
Cl
N
N
Cl
Cl
H
O
O
OEt
2 steps
iPrMgCl
CuBr · SMe2
THF, -15 °C
Cl
O
O
OEt
18
19
1716
  19 
 
Scheme 4.4 Large scale synthesis of quinoline ester 
 
 The sequence as shown in Scheme 4.2 was carried out with the goal of 
demonstrating that each step could be done on a large scale. The formation of the isatoic 
anhydride 4 was completed once, and the conversion to the quinoline 5 and chlorination 
were done twice to produce about 20 g of 6. This increase in scale led to the need for 
larger glassware and more careful handling of hazardous reagents. The synthesis began 
with anthranilic acid 3, which was reacted with triphosgene in THF. An addition funnel 
was used to ease the slow addition of the large volume of triphosgene, which was 
dissolved in THF to allow a more homogeneous mixture. Exposure to the hazardous 
fumes of triphosgene was minimized by weighing the solid quickly and then doing all 
further procedures in the fume hood. The work-up following the reaction was a simple 
filtration, though a large Buchner filter was required. The isolated pearlescent solid 4 was 
easily scraped out of the funnel into a large round bottom flask and put under high 
vacuum overnight to remove solvent, resulting in a fluffy solid.  
The second step involved the formation of quinoline 5. All reagents were added to 
a 250 mL round bottom flask which was then fitted with a reflux condenser since the 
reaction was heated to a high temperature. After quenching with distilled water and 
mechanical stirring overnight, the white precipitate was filtered out. The precipitate was 
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gummy and placed in a large round bottom that put under high vacuum overnight. During 
the first few hours, the round bottom was scraped periodically to allow more exposure to 
the vacuum. The formation of the quinoline involved only one hazardous reagent, N,N-
dimethylaniline (DMA). The exposure to this reagent was minimized by using a syringe 
to collect it from the solvent bottle, and this was done in the hood.  
The third step involved converting the alcohol 5 to the chloride 6 using 
phosphoryl chloride (POCl3). Both starting material and POCl3 were added to a 250 mL 
round bottom flask, and a condenser was used while the reaction was heated. The work-
up involved the addition of water and was more complicated on large scale due to the 
HCl gas byproduct that forms and the exothermic reaction that results. The quench was 
completed in the hood and added to ice instead of just water. The quench was done in a 
very large container to account for the increase in volume of melted ice. The reaction was 
added through a separatory funnel to control the rate and to make sure it did not add too 
fast causing the quench to heat up too quickly. Once all of the reaction had been added, 
10 M NaOH was added to neutralize the solution, and the pH was monitored using pH 
strips until a pH of 7 was reached. Once the solution was neutralized, a tan solid crashed 
out that was easily removed via Buchner funnel that was then dried under high vacuum 
overnight in a large round bottom flask. From the ester, seven more steps are needed to 
fully derivatize the quinoline scaffold to be an effective HIV integrase inhibitor. 
 Data analysis 
 Proton NMR (1H NMR) was used to confirm the formation of all products. All 
characterizations were completed by a previous graduate student’s work, so all spectra 
collected were compared to confirm the identity of products.29 The spectra for isatoic 
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anhydride 4 contained the necessary aromatic peaks and amine N-H peak with the proper 
integrations. The formation of the quinoline 5 was confirmed by the formation of new 
peaks characteristic of the ethyl side chain as well as the methyl group. The chlorination 
of the alcohol also caused a downfield shift in all peaks. A stack plot was used to 
compare the starting material and product to determine the reaction had occurred.  
4.2 MAC addition to aromatic heterocycles 
Masked acyl cyanide (MAC) reagents, such as 9, allow the addition of a one 
carbon nucleophile to a substrate, via the addition of a carbonyl (C=O) in which the 
carbon acts both as a nucleophile (-) and an electrophile (+) (Figure 4.1a). The normal 
reactivity of a C=O group is to act just as an electrophile (+). As an example, reactions in 
organic chemistry usually utilize 1,3-additions when involving C=O functional groups 
(Figure 4.1b, normal reactivity). This is due to the polarity of the C=O functional group 
which results in the carbon having a partial positive charge. The use of some reagents 
results in a polarity reversal and the ability to perform 1,2-additions (Figure 4.1b, 
umpolung reactivity). This reversal of polarity, or umpolung reactivity, allows for new 
bond disconnections to be realized that do not rely on the traditional methods of polarity. 
MAC reagents are an example of this, serving as a carbon monoxide equivalent.  
 
Figure 4.1: Normal and umpolung reactivity 
MAC reagents have been added successfully to aldehydes as the electrophile, as 
shown in Scheme 4.3. First, the MAC reagent is deprotonated with a base such as 
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dimethylaminopyridine (DMAP) and adds to the aldehyde forming adduct 20. A Brook 
rearrangement occurs, transferring the silyl group (TBS) to the alkoxide, which results in 
loss of a cyanide ion to form 21. In the presence of an alcohol, in this case ethanol, acyl 
cyanide 21 is attacked, resulting in an intermediate 22 that collapses to form the product 
10 (after proton transfer from intermediate 23). Scheme 4.3 shows the generalized 
reaction and the proposed mechanism for the MAC addition. 
 
Scheme 4.3: Generalized reaction scheme and proposed mechanism 
The ability to add MAC reagents to various types of aldehydes has not been 
accomplished in the literature using heterocycles. Our goal for this project was to explore 
the MAC addition to various heterocycles. The diverse use of heterocycles in drug 
structures and ability to apply this method to quinolines for HIV integrase inhibition 
highlight the importance of this work. As such, following the reaction in Scheme 4.3, a 
screen of various heterocyclic aldehydes was undertaken (Table 4.1). Aldehydes 24-28 
were dissolved in diethyl ether (Et2O) and ethanol (EtOH), followed by addition of MAC 
9 and then the base (DMAP). The reaction was stirred for 16 hours at room temperature 
then an extraction was performed. The crude material after extraction was checked by 1H 
NMR and then purified using column chromatography. The results are shown in Table 
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4.1 and indicate purified yields after column chromatography. The yields varied a lot and 
for the most part were relatively low. No clear trend could be observed. 
Starting material Final product Percent yield 
  
36% 
  
37% 
  
72% 
  
33% 
  
39% 
 Table 4.1: Results of MAC addition to selected aromatic heterocyclic aldehydes 
 
 To further explore the conditions, pyridyl aldehydes 25 and 26 were tried with 
various changes in conditions before purification on silica gel (Table 4.2). For 3-pyridyl 
26, two different workup conditions were tried (entries 1 and 2). The first involved 
washing with water and then extracting with dichloromethane (DCM, entry 1), while the 
second involved washing with saturated aqueous ammonium chloride (NH4Cl, entry 2). 
The two conditions did not result in a noticeable difference in yield (69% for entry 1 
versus 72% for entry 2). However, 2-pyridyl aldehyde 25 resulted in noticeably lower 
yields under these conditions (37%, entry 3). It was therefore tried to just concentrate the 
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reaction and add it directly for purification, bypassing the extraction/work-up. This also 
resulted in a disappointing yield (14%, entry 4). 
Entry Substrate Work-up 
Extraction 
conditions, if 
applicable 
Percent yield 
1 
 
Extraction and 
column 
10 mL H2O, 3-
10 mL washes 
DCM 
69% 
2 
 
Extraction and 
column 
10 mL sat. 
NH4Cl, 3-10 mL 
washed DCM 
72% 
3 
 
Extraction and 
column 
10 mL sat. 
NH4Cl, 3-10 mL 
washed DCM 
37% 
4 
 
Column only N/A 14% 
Table 4.2: Work up procedure methods 
 
 It has been seen that the reactions with aromatic heterocycles are significantly 
lower yielding than the non-heterocyclic aldehydes used in literature. It has been 
suggested that the small scale of the reactions leaves very little room for error as even 
small errors on a 0.03 mmol scale can have large impact on yield. It could also be 
possible that the lone pairs present on the heteroatoms in the structures interfere in the 
reaction conditions. At this point, the project was not further continued. 
 Data analysis 
 All reactions were monitored by 1H NMR. The data below is an example using 
the reaction with pyridine-3-carboxaldehyde. Each substrate results in unique spectra, 
however, the consistent aspect is the loss of the aldehyde peak (~10 ppm) and shifting of 
aromatic peaks (7-9 ppm). The blow-up regions show the aldehyde and aromatic regions 
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of both the starting material and product NMRs to demonstrate the loss of the aldehyde 
peak (a) and the shift of the aromatic peaks (b-e). The full spectra shows the addition of 
six new peaks indicating the addition of the new side chain consisting of a TBS 
protecting group, adjacent hydrogen, and an ethyl group. The TBS group produces three 
singlets (h, i, j). The adjacent hydrogen is also a singlet (a). A quartet and triplet (f and g, 
respectively) are the ethyl peaks.  
Aromatic region of pyridine-3-carboxaldehyde (starting material) 
 
 
 
Aromatic region of ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(pyridine-3-yl) acetate 
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Pyridine-3-carboxaldehyde (starting material) full spectrum 
 
 
 
 
Ethyl-2-((tert-butyldimethylsilyl)oxy)-2-(pyridine-3-yl) acetate full spectrum 
 
5. Conclusion 
 The two aims of this thesis center on the use of heterocycles in medicinal 
chemistry. The use of quinoline as an allosteric HIV-1 integrase inhibitor demonstrates 
the application of heterocycles in new areas of HIV treatment. Several derivatives with a 
quinoline scaffold have been synthesized through methods using commercially available 
quinolines as well as anthranilic acid derivatives. The method using commercially 
available quinolines was limited to only derivatizing certain positions and had 
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diminishing yields as the scale increased. The ability to synthesize quinoline derivatives 
on a large scale increases the possibility of its use as the scaffold for drug structures. In a 
research laboratory, it is useful to be able to produce large quantities to have plenty of 
material to subject to various tests. In addition, once a drug successfully passes through 
all clinical trials, it must be synthesized on a large scale to made available commercially.  
 One step of the quinoline derivatization involves the manipulation of the 3-
position side chain. This can be done by reducing the ethyl ester to an alcohol and 
oxidizing to an aldehyde. Once it is an aldehyde, MAC reagents can be used to install the 
desired sidechain. To further explore the use of MAC reagents to oxidize aldehydes, this 
method was applied to various aromatic heterocyclic aldehydes. The goal with this was to 
expand the application of MAC beyond the substrates used in literature. TBS-protected 
MAC reagents successfully installed the ester sidechain to the heterocycles used though 
yields varied.  
 Work has already begun to continue the synthesis route on large scale to complete 
the seven steps beyond the chlorinated quinoline ester. Further work could be done to 
continue to optimize the conditions of the MAC addition to improve yields with 
heterocycles. These two projects demonstrate the diversity in the possible applications of 
heterocycles and possible expansions to increase their use in medicinal chemistry.   
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